» Articles » PMID: 2457622

Disruption of the Internal Thioester Bond in the Third Component of Complement (C3) Results in the Exposure of Neodeterminants Also Present on Activation Products of C3. An Analysis with Monoclonal Antibodies

Overview
Journal J Immunol
Date 1988 Sep 1
PMID 2457622
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

Hydrolysis of the internal thioester bond in native C3 is thought to be a key event in initiating the alternative pathway of C activation, because the resulting C3(H2O) acquires "C3b-like" properties. Therefore, disruption of the internal thioester bond is probably accompanied by conformational changes in the C3 molecule. In this study, we demonstrate that such conformational changes indeed occur; 7 of the 19 mAb raised against C3 or C3 activation products recognized epitopes exposed on C3(H2O) but not on native C3. One of these epitopes is located on the C3a part, three on the C3c part, and another three on the C3d,g part. Because the 7 mAb bound equally well to C3 incubated either with MgCl2 or with methylamine (which primarily disrupts the thioester), the conformational changes detected by the mAb apparently occur after disruption of the thioester. Furthermore, the epitopes were also present on the corresponding C3 activation products. Immunoblotting experiments revealed that the epitopes for the three anti-C3d,g mAb were located on the C3d part, C-terminal to the thioester. The epitopes for 2 of the 3 anti-C3c mAb were located on the C-terminal alpha-chain fragment of C3c. Thus, this study provides immunochemical evidence for the biologic resemblance between C3(H2O) and C3 activation products. Implications of these findings for the activation process of C3 are discussed.

Citing Articles

Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.

Ricciuti J, Liu Q, Khan A, Joseph J, Veuskens B, Giridharan T Gynecol Oncol. 2025; 193:49-57.

PMID: 39764857 PMC: 11871990. DOI: 10.1016/j.ygyno.2024.12.006.


Praziquantel and factor H recruitment differentially affect the susceptibility of to complement-mediated damage.

van Beek A, Jeanguenat H, Haberli C, Pouw R, Lamers C, Pal G Front Immunol. 2024; 15:1474358.

PMID: 39600706 PMC: 11588701. DOI: 10.3389/fimmu.2024.1474358.


C1-inhibitor treatment in patients with severe complement-mediated autoimmune hemolytic anemia.

de Boer E, Jalink M, Delvasto-Nunez L, Meulenbroek E, Baas I, Janssen S Blood Adv. 2023; 7(13):3128-3139.

PMID: 36920779 PMC: 10362545. DOI: 10.1182/bloodadvances.2022009402.


Factors affecting IgG4-mediated complement activation.

Oskam N, Damelang T, Streutker M, Ooijevaar-De Heer P, Nouta J, Koeleman C Front Immunol. 2023; 14:1087532.

PMID: 36776883 PMC: 9910309. DOI: 10.3389/fimmu.2023.1087532.


The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation.

de Boer E, Thielen A, Langereis J, Kamp A, Brouwer M, Oskam N Clin Transl Immunology. 2023; 12(1):e1436.

PMID: 36721662 PMC: 9881211. DOI: 10.1002/cti2.1436.